脑出血后使用SSRI与出血复发及抑郁严重程度的相关性
这项纵向队列研究纳入1279例原发性脑出血存活出院患者,中位随访53.2个月。SSRI暴露与脑出血复发风险升高相关(SHR 1.31),也与抑郁症状缓解相关(SHR 1.53);高复发风险患者使用SSRI时复发风险进一步升高(SHR 1.79)。
要点
- 脑出血后使用SSRI与出血复发风险升高相关(SHR 1.31)。
- SSRI使用也与抑郁症状缓解相关(SHR 1.53)。
- 高复发风险患者使用SSRI时复发风险更高(SHR 1.79)。
核心结论
- 脑出血后SSRI暴露与抑郁症状改善及出血性卒中复发风险增加均相关。
- 临床病史、神经影像和遗传生物标志物可能有助于识别更能安全耐受SSRI的脑出血存活者。
研究设计与样本
- 纵向脑出血队列研究,单中心三级医疗中心,2006年1月至2017年12月入组。
- 纳入1279例原发性脑出血后存活出院的患者,中位随访53.2个月(四分位距42.3-61.2个月)。
主要发现
- SSRI暴露与脑出血复发相关(SHR 1.31;95% CI 1.08-1.59)。
- SSRI暴露与脑出血后抑郁缓解相关(SHR 1.53;95% CI 1.12-2.09)。
- SSRI与抑郁症状减轻的关联在高复发风险患者与其他存活者间无差异。
关键数值与推荐
- 高复发风险特征包括:脑叶出血、载脂蛋白ε2/ε4基因变异、既往脑出血/TIA/缺血性卒中史、黑人或西班牙裔种族。
临床怎么用
- 对脑出血存活者处方SSRI时,应权衡抑郁症状改善的获益与出血复发的风险。
- 可结合临床病史、神经影像和遗传生物标志物评估患者复发风险,以辅助SSRI决策。
局限性
- 单中心队列研究,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat poststroke depression but are associated with increased incidence of first-ever intracerebral hemorrhage (ICH) in the general population. The decision to treat ICH survivors with SSRIs must therefore balance potential risks of ICH recurrence with presumed benefits on depressive symptoms. OBJECTIVE: To determine whether SSRI use among survivors of primary ICH was associated with ICH recurrence and decreased severity of depressive symptoms. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal ICH cohort study at a tertiary care center enrolling from January 2006 to December 2017, with follow-up for a median of 53.2 months (interquartile range, 42.3-61.2 months). The study included 1279 consenting individuals (1049 White, 89 Black, 77 Hispanic, and 64 other race/ethnicity) of 1335 eligible patients presenting with primary ICH and who were discharged alive from initial hospitalization for stroke. MAIN OUTCOMES AND MEASURES: We conducted univariable and multivariable analyses for ICH recurrence risk and depression severity, including subset analyses for patients with 1 or more of the following characteristics associated with high ICH recurrence risk: (1) lobar ICH; (2) presence of the apolipoprotein ε2/ε4 gene variants; (3) prior history of ICH/TIA/ischemic stroke; and (4) Black or Hispanic race/ethnicity. RESULTS: Mean age of study participants was 71.3 years, with 602 women (47%); of the 1279 participants, 1049 were White, 89 were Black, 77 were Hispanic, and 64 were other race/ethnicity. SSRI exposure was associated with both ICH recurrence (subhazard ratio [SHR], 1.31; 95% CI, 1.08-1.59) and resolution of post-ICH depression (SHR, 1.53; 95% CI, 1.12 2.09). Among those individuals at high risk for recurrent ICH, SSRIs were associated with further elevation in risk for ICH recurrence (SHR, 1.79; 95% CI, 1.22-2.64) compared with all other survivors of ICH (SHR, 1.20; 95% CI, 1.01-1.42; P = .008 for comparison of effect sizes). The association of SSRI with reduced depressive symptoms did not differ between high those at high risk for recurrent ICH and all other ICH survivors. CONCLUSIONS AND RELEVANCE: Selective serotonin reuptake inhibitor exposure after ICH is associated with both improvement in depressive symptoms and increased risk of recurrent hemorrhagic stroke. Clinical history, neuroimaging data, and genetic biomarkers may help to identify survivors of ICH more likely to safely tolerate SSRI use.
引用
- Kubiszewski P, Sugita L, Kourkoulis C, et al. Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity. JAMA Neurol. 2020. PMID: 32865558. doi:10.1001/jamaneurol.2020.3142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。